Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

ADP-ribosylation (ADPRylation) is a post-translational modification of proteins catalyzed by
ADP-ribosyl transferase (ART) enzymes, including nuclear PARPs (eg, PARP1 and PARP2) …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …